




**A****B**

**Fig. S1. (A)** FIBP expression profile across multiple TCGA tumor and paired normal tissues. **(B)** FIBP protein levels in a human lung adenocarcinoma tissue microarray containing 82 paired lung adenocarcinoma and adjacent lung tissues.



**Fig. S2. FIBP silencing inhibits non-small cell lung cancer cell proliferation.** (A) CFSE was used to evaluate the proliferation ability of lung cancer cells. (B) FIBP downregulation reduced the population of S phase cells. \*\*P < 0.01, \*\*\*P < 0.001. (C) The percentage of EdU-positive cells in FIBP-depleted lung cancer cells was decreased. \*\*\*P < 0.001.



**Fig. S3. The mRNA and protein expression of FIBP and EME1 in the animal model. (A)**  
 Real-time PCR analysis showed the mRNA expression of FIBP and EME in xenograft tumors (n = 6). \*\*\*P < 0.001. **(B)** Immunoblot analysis of FIBP and EME1 protein levels in xenograft tumors (n = 6).

**Supplemental Table S1.** Primers Sequences used for Real-time PCR

Genes	Sequences (5'-3')
BLM	F: CAGACTCCGAAGGAAGTTGTATG R: TTTGGGGTGGTGTAAACAAATGAT
BRIP1	F: CTTACCCGTACAGCTTGCTA R: CACTAAGAGATTGTTGCCATGCT
RAD54L	F: AGGCAGGTCCCTGTGATGATGA R: TCAAAGGTTCCGAAAAGGAGAC
POLD1	F: ATCCAGAACCTCGACCTTCG R: ACGGCATTGAGCGTGTAGG
EME1	F: TTCCAGCCTACCTGTCTA R: TTTCTTCCTGTCTTCTCA
FIBP	F: CTTCCAGATTCCGCCCTCC R: AGCACCTCCCGAACAAAGG
GAPDH	F: GGAGCGAGATCCCTCCAAAAT R: GGCTGTTGTCATACTTCTCATGG

<sup>a</sup> F, forward primer; R, reverse primer.

**Supplementary Table S2.** Primers Sequences used for ChIP PCR

Numbers	Sequences (5'--3')
#1	F: CTACAGAGAAAGGACCCACCC R: CGTGAGTGAGGGCGTTGA
#2	F: TCTTCAAACGCCCTCACTCA R: GAGGGGAAGTGTGTGGGGTA
#3	F: GATCAGTGTCACCTCCTCCCC R: AATGGGACGCAGTAGTCAGA
#4	F: CACCCGCTCTGACTACTG R: TTTCGAGACCGGAAGTGAGT
#5	F: CCATGCTTCGATCACTCACTTC R: ACTTCTCCGCCACTCTTCA
#6	F: AAGAGTGGCGGGAGAAGTTG R: CTCCTGGACACCTTAGCCAC
#7	F: ACACCGCTCTGCAGAACATT R: GCAAATCAGGGAGTGGGAC
#8	F: GTCCCACCTCCCTGATTGC R: GGCACACAGCTGGCTAAGTA

F, forward primer; R, reverse primer.